Skip to content

The efficacy and safety of 2% chlorhexidine gluconate in 70% alcohol compared with 10% povidone iodine in blood culture in neonates

The efficacy and safety of 2% chlorhexidine gluconate in 70% alcohol compared with 10% povidone iodine in blood culture in neonates

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
TCTR
Registry ID
TCTR20160419001
Enrollment
328
Registered
2016-04-19
Start date
2016-03-15
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Data on the efficacy of topical antiseptics for prevention of culture contamination in neonates have been very limited. 8 Therefore&#44

Interventions

Chlorhexidine gluconate is an alternative skin antiseptic&#44
which has been reported as being superior to povidone iodine.CHG has a broad&#45
spectrum bactericidal activity with a rapid onset of action by bacterial cell wall disruption. Meta&#45
analyses have also shown that CHG is more effective in skin disinfection than PI in prevention of central venous catheter–related infection. Therefore&#44
the Centers for Disease Control and Prevention has recom&#45
mended CHG as a topical antiseptic for adults and infants greater than 2 months of age.,10% povidone iodine are generally used to clean the patients’ skin before taking blood. PI&#44
has a bactericidal action by diffusion through the bacterial cell wall and inhibition of intracellular protein and nucleic acid synthesis&#44
and its onset of action takes longer than that of CHG.
Experimental Drug,Experimental Drug
Chlorhexidine group (CHG),Povidone iodine group (PI)

Sponsors

Thammasat University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
0 Years to 1 Months

Inclusion criteria

Inclusion criteria: Neonates with birth weight of at least 1,500 g who required blood culture were included. Eligible infants were then ran- domly allocated into either the PI group or the CHG group.

Exclusion criteria

Exclusion criteria: - patients who has history of antiseptics allegy or has skin infection at puncture site - patients who uneligible

Design outcomes

Primary

MeasureTime frame
efficay none contamination rate

Secondary

MeasureTime frame
adverse effects 2 days after use antiseptics observation

Countries

Thailand

Contacts

Public ContactPimprae Pengpis

Unaffiliated

tasneam@hotmail.com0898455443

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026